rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Phathom Pharmaceuticals, Inc.

PHAT · Nasdaq

Health CareBiotechnologyNot moving yet

PHAT stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 36 weeks. It is 30.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 36
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$7,079
Officials’ trades on record
0
Institutions holding
155 (-9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$206K$0$201KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders155-9 on the quarter
New · exited24 · 33
Reported value$760.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Frazier Life Sciences Management, L.P.unchanged · filed 14 Aug 202612,466,489$135.3M00.0%
Medicxi Ventures Management (Jersey) Ltdunchanged · filed 4 Aug 20267,464,572$81.0M00.0%
BlackRock, Inc.added · filed 7 Aug 20264,525,129$49.1M+463,133+11.4%
Invesco Ltd.reduced · filed 14 Aug 20264,029,731$43.7M-292,329−6.8%
Carlyle Group Inc.unchanged · filed 7 Aug 20263,496,808$37.9M00.0%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20263,375,834$36.6M-647,075−16.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,656,944$28.8M+73,308+2.8%
FRANKLIN RESOURCES INCadded · filed 13 Aug 20261,970,828$21.4M+976,324+98.2%
NEA Management Company, LLCunchanged · filed 14 Aug 20261,960,169$21.3M00.0%
683 Capital Management, LLCunchanged · filed 14 Aug 20261,850,000$20.1M00.0%
31 Mar 2023 – 30 Jun 2026
67114160Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Sanjeev Narula Company insiderChief Financial & Bus. Officer · last 6 Oct 20260 · 0
Robert Charles Breedlove Company insiderPrincipal Accounting Officer · last 3 Sep 20260 · 3
Asit Parikh Company insiderDirector · last 22 May 202611 · 0
Frank Karbe Company insiderDirector · last 19 May 20261 · 0
Heidi Fields Company insiderDirector · last 19 May 20260 · 0
James N. Topper Company insiderDirector, 10% owner · last 19 May 20265 · 0
Mark Stenhouse Company insiderDirector · last 19 May 20260 · 0
Michael F. Cola Company insiderDirector · last 19 May 20261 · 0
Theodore R. Schroeder Company insiderDirector · last 19 May 20260 · 0
Anne Marie Cook Company insiderChief Legal Off. & Corp. Sec. · last 10 Feb 20260 · 0
Steven L. Basta Company insiderPresident and CEO · last 10 Feb 20260 · 0
Molly Henderson Company insiderCFO and CBO · last 7 Apr 20251 · 13

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202587.1%
Operating profit marginFY 2025 · to 31 Dec 2025-91.4%
Free cash flow marginFY 2025 · to 31 Dec 2025-95.4%
Return on capital employedFY 2025 · to 31 Dec 2025-126%
Research spendFY 2025 · to 31 Dec 202518.7%
Share count trendFY 2025 · to 23 Feb 202610.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$130.0M
Free cash flowFY 2025 · to 31 Dec 2025−$167.0M

Analyst forecasts

No analyst forecasts yet.